The Microdose

Home
This Week in Psychedelics
5 Questions
Opinion
Archive
About
Psychedelic reform coming soon to a ballot box near you: 5 Questions for New Approach deputy policy director Jared Moffat
Moffat discusses New Approach’s plans for the future.
 • 
jane c. hu
4
Congressman from California introduces national psilocybin legislation; Kentucky holds ibogaine public hearing while California lawmaker…
Plus: European Medicines Agency acknowledges psilocybin as depression treatment, and How does psychedelic-assisted therapy work?
 • 
jane c. hu
Heart risks, serotonin, and fen-phen: 5 Questions for 5-HT receptor researcher Bryan Roth
Roth discusses what we know about drugs that stimulate 5-HT receptors and their effect on the heart.
 • 
jane c. hu
12
Most Popular
View all
Welcome to The Microdose
 • Michael Pollan
67
Oregon’s first psilocybin client: 5 Questions for retired home builder Jim Carroccio
 • jane c. hu
40
Mixing antidepressants and psychedelics: 5 Questions for psychopharmacologist Kelan Thomas
 • jane c. hu
14
Dispatches from Denver: Day 1 at Psychedelic Science 2023
 • jane c. hu
Jeffrey Sitting Bear, Peyote, and Hippies
 • Simon Moya-Smith
8
New
Top
Community
California psychedelics bill headed to Gov Newsom and proposed ballot initiative will cost $6.6 billion over 30 years; New clinical trial…
Australian psychedelics leaders surveyed on the rollout of legal therapeutic MDMA and psilocybin, Canadian peyote company goes public, and UK Committee…
 • 
jane c. hu
Engineering non-hallucinogenic psychedelics: 5 Questions for researcher David Olson
Olson discusses the potential of psychoplastogens and the intersection of academic research and private companies in the psychedelics space.
 • 
jane c. hu
4
New clinical trial results suggest a single psilocybin dose can significantly reduce depression symptoms for weeks; Comments on FDA’s draft…
Plus: State updates in CA and MA, and a call for a psychedelics advisory group in the EU
 • 
jane c. hu
3
Hallucinogen use on the rise in the U.S., Does adding MDMA to psilocybin or LSD result in fewer bad trips? And Cybin acquires Small Pharma
Plus: Indigenous psychedelics coalition in Colorado calls for reciprocity and respect, and more state news
 • 
jane c. hu
1
Liability insurance for psychedelics: 5 Questions for insurance expert Leslie Nylund
Nylund discusses Baldwin Risk Partners' new liability insurance for psychedelics practitioners
 • 
jane c. hu
1
Self-administering psychedelics to treat OCD; California psychedelics bill on pause, Massachusetts ballot initiatives filed; and new…
Plus: The murky future of ketamine telehealth, and nihilism and psychedelics
 • 
jane c. hu
1
“Net-zero trauma by 2070”: 5 Questions for MAPS founder Rick Doblin
Doblin discusses his vision for a world with "net-zero trauma."
 • 
jane c. hu
8
The Microdose
The Microdose
An independent journalism newsletter supported by the U.C. Berkeley Center for the Science of Psychedelics

The Microdose

AboutArchiveSitemap
© 2023 UC Berkeley Center for the Science of Psychedelics
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing